Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics develops targeted immunotherapies that attack solid tumors and aim to enhance the immune system's ability to combat cancer. The company is involved in clinical trials for its neural stem cells engineered to carry an oncolytic virus for treating recurrent high-grade glioma.

Calidi Biotherapeutics

Calidi Biotherapeutics | 2,536 followers on LinkedIn. Calidi Biotherapeutics is a clinical-stage biopharmaceutical company | Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

Quality Assurance Leader in Biotech/Pharma

Violet M. Carvalho

Chief Financial Officer

Andrew Jackson

Cofounder and Vice Chairman of Board of Directors Calidi Biotherapeutics

Scott Leftwich

Chief Business and Revenue Officer | Global

Steve Thesing

👏 Calidi Biotherapeutics recognizes Wendy Pizarro, Esq. , our Chief Legal Officer and Chief Diversity Officer, as a speaker today, October 21, 2024, at the San Diego Precision in Clinical Trials Summit in San Diego, CA. Sherri Monroe She will be speaking on Diversity, Equity and Inclusion Strategies in Clinical Trials and Patient Recruitment. Please reach out to her if you will be attending! #calidi #clinicaltrials #PCTSUMMIT #DEI #endcancer $CLDI

Calidi Biotherapeutics ' Chief Business Officer, Steve Thesing , recently interviewed with Dave Gentry , CEO of RedChip Companies , discussing Calidi's cancer therapies and their place in the future of oncology. Click below for the full interview: #calidi #oncology #virotherapy #endcancer $CLDI

Congratulations to Calidi Biotherapeutics ' Chief Legal Officer and Chief Diversity Officer, Wendy Pizarro, Esq. , for being awarded as a "2024 DEIA Visionary" by the L.A. Times B2B Publishing for her advocacy on health equity in innovative clinical trials. Read more here: https://lnkd.in/gd5v6aVf #DEI #healthequity #deia #indigenouspeoplesday

Calidi Biotherapeutics is thrilled to announce FDA Clearance of the Northwestern University IND Application for Calidi's NeuroNova (CLD-101) Clinical Trial in Newly Diagnosed High-Grade Glioma. Congratulations to the NWU and Calidi teams! Read more below: #calidi #IND #clinicaltrial #virotherapy #neuronova $CLDI #glioblastoma #highgradeglioma #braincancer

Missed Our Virtual Presentation? Watch the Replay Now! Yesterday, we at Calidi Biotherapeutics hosted an exciting virtual presentation diving deep into the groundbreaking science and innovative technology we’re developing to combat cancer. If you missed it, don’t worry! You can catch the full replay and discover how our pioneering approaches are transforming the future of cancer treatment. Watch the Replay Here: https://lnkd.in/gnGR7Fmf Join us on this journey towards a world free from the threat of cancer. Your support and curiosity drive our mission forward! #CalidiBio #CancerResearch #Biotechnology #Innovation #Science #Healthcare

Join Us for an Exciting Webinar: Calidi’s Groundbreaking Cancer Treatment 📅 Date: September 11th 🕓 Time: 4:15 PM ET Discover the future of cancer treatment with Calidi! Our developmental drug targets and destroys cancer cells throughout the body while leaving healthy cells unharmed. Don’t miss this opportunity to learn more about this revolutionary therapy. 🔗 Register now: #calidi #virotherapy #endcancer $CLDI

Calidi Biotherapeutics was recently featured in an article by Fred Grier with the San Diego Business Journal , highlighting the launch of our new subsidiary, Nova Cell. Read more below! #calidi #novacell #stemcells #biotech #sandiego $CLDI

📣 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results. Read more below! #calidi #virotherapy #stemcells #biotech $CLDI

Calidi Biotherapeutics is proud to announce the launch of our new subsidiary, Nova Cell, and a $3 million aggregate investment from Dr. Ronald Rigor. Dr. Rigor, an accomplished Board-Certified Dermatologist, Internal Medicine, and Stem Cell Therapy expert has taken a significant step to advance regenerative medicine by investing in Nova Cell. “As the founder of one of the largest and fastest growing stem cell centers in the Philippines, I am delighted to partner with and invest in Nova Cell. This is a fantastic opportunity to provide best-in-class stem cell therapy treatments which could meet a huge unmet need in the Philippines. We look forward to bringing Nova Cell’s extensive experience in stem cell therapy production to provide innovative therapies to patients and to elevate the health and wellness industry in the Philippines.” - Dr. Rigor Read more below: #stemcell #calidi #NovaCell $CLDI

Calidi Biotherapeutics recently announced the issuance of a new U.S. patent covering our novel SuperNova technology! “This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone, as we prepare to advance CLD-201 into the clinic." - Allan Camaisa, CEO and Chairman. Read more below: #calidi #patent #SuperNova #virotherapy #stemcells $CLDI

Metric
Company Name	Calidi Biotherapeutics, Inc.
Symbol	CLDI
MSH ID	COM:CALIDIBIO
Market	STOCKS
Sector
Industry
Country	US
Stage	Post-IPO Equity
Employee Count	41
Website	calidibio.com
LinkedIn	calidibiotherapeutics
Founders

Metric
Market Cap	35.21M
Enterprise Value
Monthly Web Traffic	2.46K
Web Traffic Growth	1.22
Valuation
Raised Capital	2M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CALIDIBIO

Calidi Biotherapeutics

Last Close

2.15

22/11 21:00

Market Cap

25.63M

Beta: -

Volume Today

1.48M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue